Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study - COV-ENOX

CHU de Saint Etienne0 个研究点目标入组 200 人开始时间: 2020年4月15日最近更新: 2020年5月4日

适应症

试验速览

暂无简介。

•- Adult patients at least 18 years of age
•- Patients hospitalized in the intensive care unit infected with SARS-CoV-
•2, for whom a diagnosis of respiratory SARS-CoV-2 infection was made
•by nasopharyngeal swab or deep respiratory sampling (patients on HDON or artificial ventilation)
•- Patient receiving enoxaparin therapy as part of care or as part of a clinical trial for the prevention or treatment of thromboembolic venous disease.
•- Patient affiliated or entitled to a social security scheme
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

•- Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWHs)
•- History of immune-mediated heparin-induced thrombocytopenia (HIT) in the last 100 days or in the presence of circulating antibodies
•- Active clinically significant bleeding or a condition associated with a high risk of bleeding, such as a recent hemorrhagic stroke, gastrointestinal ulcer, the presence of a malignant tumour at high risk of bleeding, recent brain, spinal or ophthalmologic surgery, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysm or major intrarachid or intracerebral vascular abnormalities.
•- Spinal, epidural or locoregional anaesthesia or anaesthesia when enoxaparin sodium is used for curative treatment within the previous 24 hours

发起方

CHU de Saint Etienne